PROfiling Based Endometrial Cancer Adjuvant Therapy

This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.

NCT Number	NCT05179447
Lead Sponsor	Women's Hospital School Of Medicine Zhejiang University Collaborators: Tongji Hospital, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, Sun Yat-sen University, Peking University People's Hospital, Shanghai First Maternity and Infant Hospital, Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Ningbo Women & Children's Hospital, Ningbo No. 1 Hospital
Conditions	Endometrial Cancer Stage I, Endometrial Cancer Stage II
Enrollment	590 participants
Start Date	2022-01-24
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-01-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-01